Epilepsy Drugs Market Report and Forecast 2024-2032

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions
    1.3    Report Coverage – Key Segmentation and Scope 
    1.4    Research Methodology
2    Executive Summary
3     Epilepsy Drugs Market Overview: 8 Major Market 
    3.1     Epilepsy Drugs Market Historical Value (2017-2023) 
    3.2     Epilepsy Drugs Market Forecast Value (2024-2032)
4    Vendor Positioning Analysis
    4.1    Key Vendors
    4.2    Prospective Leaders
    4.3    Niche Leaders
    4.4    Disruptors 
5    Epilepsy: Disease Overview 
    5.1    Guidelines and Stages
    5.2    Pathophysiology
    5.3    Screening and Diagnosis
    5.4    Therapy Pathway
6    Patient Profile
    6.1    Patient Profile Overview
    6.2    Patient Psychology and Emotional Impact Factors
    6.3    Risk Assessment and Therapy Success Rate
7    Epilepsy Epidemiology Scenario and Forecast – 8 Major Markets
    7.1    8MM Epidemiology Scenario Overview (2017-2032)
        7.1.1    Prevalence, by Country
            7.1.1.1    U.S.
            7.1.1.2    U.K.
            7.1.1.3    EU4
            7.1.1.4    India 
            7.1.1.5    Japan
        7.1.2    Mortality, by Country
            7.1.2.1    U.S.
            7.1.2.2    U.K.
            7.1.2.3    EU4
            7.1.2.4    India 
            7.1.2.5    Japan
        7.1.3    Treatment Seeking Rate, by Country
            7.1.3.1    U.S.
            7.1.3.2    U.K.
            7.1.3.3    EU4
            7.1.3.4    India 
            7.1.3.5    Japan
8    Epilepsy Drugs Market Landscape: 8 Major Market*
    8.1     Epilepsy Drugs Market: Developers Landscape
        8.1.1    Analysis by Year of Establishment
        8.1.2    Analysis by Company Size
        8.1.3    Analysis by Region
    8.2     Epilepsy Drugs Market: Product Landscape
        8.2.1    Analysis by Seizure Type
        8.2.2    Analysis by Drug Generation
9    Epilepsy Market Therapy Challenges and Unmet Needs
    9.1    Therapy Pathway Challenges
    9.2    Compliance and Drop-Out Analysis
    9.3    Awareness and Prevention Gaps
10    Cost of Therapy
11     Epilepsy Drugs Market Dynamics
    11.1     Market Drivers and Constraints
    11.2     SWOT Analysis
        11.2.1    Strengths
        11.2.2    Weaknesses
        11.2.3    Opportunities
        11.2.4    Threats
    11.3     PESTEL Analysis 
        11.3.1    Political 
        11.3.2    Economic 
        11.3.3    Social 
        11.3.4    Technological 
        11.3.5    Legal 
        11.3.6    Environment
    11.4     Porter’s Five Forces Model
        11.4.1    Bargaining Power of Suppliers
        11.4.2    Bargaining Power of Buyers
        11.4.3    Threat of New Entrants
        11.4.4    Threat of Substitutes
        11.4.5    Degree of Rivalry
    11.5     Key Demand Indicators 
    11.6    Key Price Indicators
    11.7    Industry Events, Initiatives, and Trends 
    11.8    Value Chain Analysis
12     Epilepsy Drugs Market Segmentation (2017-2032): 8 Major Market
    12.1     Epilepsy Drugs Market (2017-2032) by Seizure Type
        12.1.1    Market Overview
        12.1.2    Focal Seizures
        12.1.3    Generalized Seizures
        12.1.4    Non-epileptic Seizures
        12.1.5    Others
    12.2     Epilepsy Drugs Market (2017-2032) by Drug Generation 
        12.2.1    Market Overview
        12.2.2    First Generation Drugs
        12.2.3    Second Generation Drugs
        12.2.4    Third Generation Drugs
    12.3     Epilepsy Drugs Market (2017-2032) by Age Group
        12.3.1    Market Overview
        12.3.2    Pediatric
        12.3.3    Geriatric
        12.3.4    Adult
    12.4     Epilepsy Drugs Market (2017-2032) by Route of Administration
        12.4.1    Market Overview
        12.4.2    Oral
        12.4.3    Nasal
        12.4.4    Injectable 
        12.4.5    Others
    12.5     Epilepsy Drugs Market (2017-2032) by Distribution Channel 
        12.5.1    Market Overview
        12.5.2    Hospital Pharmacies
        12.5.3    Drug Stores and Retail Pharmacies
        12.5.4    Online Providers
    12.6     Epilepsy Drugs Market (2017-2032) by Region
        12.6.1    Market Overview
        12.6.2    United States
        12.6.3    EU-4 and the United Kingdom
            12.6.3.1    Germany
            12.6.3.2    France
            12.6.3.3    Italy
            12.6.3.4    Spain
            12.6.3.5    United Kingdom
        12.6.4    Japan
        12.6.5    India
13    United States Epilepsy Drugs Market (2017-2032)
    13.1     United States Epilepsy Drugs Market Historical Value (2017-2023) 
    13.2     United States Epilepsy Drugs Market Forecast Value (2024-2032)
    13.3     United States Epilepsy Drugs Market (2017-2032) by Seizure Type
        13.3.1    Market Overview
        13.3.2    Focal Seizures
        13.3.3    Generalized Seizures
        13.3.4    Non-epileptic Seizures
        13.3.5    Others
    13.4      United States Epilepsy Drugs Market (2017-2032) by Drug Generation 
        13.4.1    Market Overview
        13.4.2    First Generation Drugs
        13.4.3    Second Generation Drugs
        13.4.4    Third Generation Drugs
    13.5      United States Epilepsy Drugs Market (2017-2032) by Age Group
        13.5.1    Market Overview
        13.5.2    Pediatric
        13.5.3    Geriatric
        13.5.4    Adult
    13.6      United States Epilepsy Drugs Market (2017-2032) by Route of Administration
        13.6.1    Market Overview
        13.6.2    Oral
        13.6.3    Nasal
        13.6.4    Others
    13.7      United States Epilepsy Drugs Market (2017-2032) by Distribution Channel 
        13.7.1    Market Overview
        13.7.2    Hospital Pharmacies
        13.7.3    Drug Stores and Retail Pharmacies
        13.7.4    Online Providers
14    EU-4 and United Kingdom Epilepsy Drugs Market (2017-2032)
    14.1    EU-4 and United Kingdom Epilepsy Drugs Market Historical Value (2017-2023)
    14.2    EU-4 and United Kingdom Epilepsy Drugs Market Forecast Value (2024-2032)
    14.3     EU-4 and United Kingdom Epilepsy Drugs Market (2017-2032) by Seizure Type
        14.3.1    Market Overview
        14.3.2    Focal Seizures
        14.3.3    Generalized Seizures
        14.3.4    Non-epileptic Seizures
        14.3.5    Others
    14.4     EU-4 and United Kingdom Epilepsy Drugs Market (2017-2032) by Drug Generation 
        14.4.1    Market Overview
        14.4.2    First Generation Drugs
        14.4.3    Second Generation Drugs
        14.4.4    Third Generation Drugs
    14.5     EU-4 and United Kingdom Epilepsy Drugs Market (2017-2032) by Age Group
        14.5.1    Market Overview
        14.5.2    Pediatric
        14.5.3    Geriatric
        14.5.4    Adult
    14.6     EU-4 and United Kingdom Epilepsy Drugs Market (2017-2032) by Route of Administration
        14.6.1    Market Overview
        14.6.2    Oral
        14.6.3    Nasal
        14.6.4    Injectable 
        14.6.5    Others
    14.7     EU-4 and United Kingdom Epilepsy Drugs Market (2017-2032) by Distribution Channel 
        14.7.1    Market Overview
        14.7.2    Hospital Pharmacies
        14.7.3    Drug Stores and Retail Pharmacies
        14.7.4    Online Providers
15    Japan Epilepsy Drugs Market
    15.1    Japan Epilepsy Drugs Market Historical Value (2017-2023) 
    15.2    Japan Epilepsy Drugs Market Forecast Value (2024-2032)
    15.3    Japan Epilepsy Drugs Market (2017-2032) by Seizure Type
        15.3.1    Market Overview
        15.3.2    Focal Seizures
        15.3.3    Generalized Seizures
        15.3.4    Non-epileptic Seizures
        15.3.5    Others
    15.4     Japan Epilepsy Drugs Market (2017-2032) by Drug Generation 
        15.4.1    Market Overview
        15.4.2    First Generation Drugs
        15.4.3    Second Generation Drugs
        15.4.4    Third Generation Drugs
    15.5     Japan Epilepsy Drugs Market (2017-2032) by Age Group
        15.5.1    Market Overview
        15.5.2    Pediatric
        15.5.3    Geriatric
        15.5.4    Adult
    15.6    Japan Epilepsy Drugs Market (2017-2032) by Route of Administration
        15.6.1    Market Overview
        15.6.2    Oral
        15.6.3    Nasal
        15.6.4    Injectable 
        15.6.5    Others
    15.7     Japan Epilepsy Drugs Market (2017-2032) by Distribution Channel 
        15.7.1    Market Overview
        15.7.2    Hospital Pharmacies
        15.7.3    Drug Stores and Retail Pharmacies
        15.7.4    Online Providers
16    India Epilepsy Drugs Market
    16.1    India Epilepsy Drugs Market (2017-2032) Historical Value (2017-2023) 
    16.2    India Epilepsy Drugs Market (2017-2032) Forecast Value (2024-2032)
    16.3    India Epilepsy Drugs Market (2017-2032) by Seizure Type
        16.3.1    Market Overview
        16.3.2    Focal Seizures
        16.3.3    Generalized Seizures
        16.3.4    Non-epileptic Seizures
        16.3.5    Others
    16.4    India Epilepsy Drugs Market (2017-2032) by Drug Generation 
        16.4.1    Market Overview
        16.4.2    First Generation Drugs
        16.4.3    Second Generation Drugs
        16.4.4    Third Generation Drugs
    16.5    India Epilepsy Drugs Market (2017-2032) by Age Group
        16.5.1    Market Overview
        16.5.2    Pediatric
        16.5.3    Geriatric
        16.5.4    Adult
    16.6    India Epilepsy Drugs Market (2017-2032) by Route of Administration
        16.6.1    Market Overview
        16.6.2    Oral
        16.6.3    Nasal
        16.6.4    Injectable 
        16.6.5    Others
    16.7    India Epilepsy Drugs Market (2017-2032) by Distribution Channel 
        16.7.1    Market Overview
        16.7.2    Hospital Pharmacies
        16.7.3    Drug Stores and Retail Pharmacies
        16.7.4    Online Providers
17    Regulatory Framework
    17.1     Regulatory Overview
        17.1.1    US FDA
        17.1.2    EU EMA
        17.1.3    INDIA CDSCO
        17.1.4    JAPAN PMDA
        17.1.5    Others
18    Patent Analysis
    18.1     Analysis by Type of Patent
    18.2     Analysis by Publication Year
    18.3     Analysis by Issuing Authority
    18.4     Analysis by Patent Age
    18.5     Analysis by CPC Analysis
    18.6     Analysis by Patent Valuation 
    18.7     Analysis by Key Players
19    Clinical Trial Analysis
    19.1    Analysis by Trial Registration Year
    19.2    Analysis by Trial Status
    19.3    Analysis by Trial Phase
    19.4    Analysis by Therapeutic Area
    19.5    Analysis by Geography
20    Grants Analysis
    20.1     Analysis by Year
    20.2     Analysis by Amount Awarded
    20.3     Analysis by Issuing Authority
    20.4     Analysis by Grant Application
    20.5     Analysis by Funding Institute
    20.6     Analysis by Departments
    20.7     Analysis by Recipient Organization 
21    Strategic Analysis
    21.1     Analysis by Partnership Instances
    21.2     Analysis by Type of Partnership
    21.3     Analysis by Leading Players
    21.4     Analysis by Geography
22    Supplier Landscape
    22.1    Market Share by Top 5 Companies  
    22.2      UCB Pharma S.A 
        22.2.1    Financial Analysis
        22.2.2    Product Portfolio
        22.2.3    Demographic Reach and Achievements
        22.2.4    Mergers and Acquisitions
        22.2.5    Certifications 
    22.3    GlaxoSmithKline Plc 
        22.3.1    Financial Analysis
        22.3.2    Product Portfolio
        22.3.3    Demographic Reach and Achievements
        22.3.4    Mergers and Acquisitions
        22.3.5    Certifications
    22.4    Sanofi 
        22.4.1    Financial Analysis
        22.4.2    Product Portfolio
        22.4.3    Demographic Reach and Achievements
        22.4.4    Mergers and Acquisitions
        22.4.5    Certifications
    22.5    S K Biopharmaceuticals     
        22.5.1    Financial Analysis
        22.5.2    Product Portfolio
        22.5.3    Demographic Reach and Achievements
        22.5.4    Mergers and Acquisitions
        22.5.5    Certifications
    22.6    Eisai Co., Ltd .
        22.6.1    Financial Analysis
        22.6.2    Product Portfolio
        22.6.3    Demographic Reach and Achievements
        22.6.4    Mergers and Acquisitions
        22.6.5    Certifications
    22.7    Novartis AG 
        22.7.1    Financial Analysis
        22.7.2    Product Portfolio
        22.7.3    Demographic Reach and Achievements
        22.7.4    Mergers and Acquisitions
        22.7.5    Certifications
    22.8    Novel Laboratories Inc .
        22.8.1    Financial Analysis
        22.8.2    Product Portfolio
        22.8.3    Demographic Reach and Achievements
        22.8.4    Mergers and Acquisitions
        22.8.5    Certifications
    22.9    Pfizer Inc .
        22.9.1    Financial Analysis
        22.9.2    Product Portfolio
        22.9.3    Demographic Reach and Achievements
        22.9.4    Mergers and Acquisitions
        22.9.5    Certifications
    22.10    Neurelis, Inc .
        22.10.1    Financial Analysis
        22.10.2    Product Portfolio
        22.10.3    Demographic
        22.10.4    Mergers and Acquisitions
        22.10.5    Certifications
    22.11    Dr. Reddy’s Laboratories 
        22.11.1    Financial Analysis
        22.11.2    Product Portfolio
        22.11.3    Demographic Reach and Achievements
        22.11.4    Mergers and Acquisitions
        22.11.5    Certifications 
    22.12    Sumitomo Pharma 
        22.12.1    Financial Analysis
        22.12.2    Product Portfolio
        22.12.3    Demographic Reach and Achievements
        22.12.4    Mergers and Acquisitions
        22.12.5    Certifications  
    22.13    Jazz Pharmaceuticals, Inc .
        22.13.1    Financial Analysis
        22.13.2    Product Portfolio
        22.13.3    Demographic Reach and Achievements
        22.13.4    Mergers and Acquisitions
        22.13.5    Certifications 
    22.14    Sun Pharmaceuticals Industries Ltd .
        22.14.1    Financial Analysis
        22.14.2    Product Portfolio
        22.14.3    Demographic Reach and Achievements
        22.14.4    Mergers and Acquisitions
        22.14.5    Certifications 
    22.15    Alkem Laboratories Ltd 
        22.15.1    Financial Analysis
        22.15.2    Product Portfolio
        22.15.3    Demographic Reach and Achievements
        22.15.4    Mergers and Acquisitions
        22.15.5    Certifications 
23     Epilepsy Drugs Market – Distribution Model (Additional Insight)
    23.1     Overview 
    23.2     Potential Distributors 
    23.3     Key Parameters for Distribution Partner Assessment 
24    Key Opinion Leaders (KOL) Insights (Additional Insight)
25    Payment Methods (Additional Insight)
    25.1     Government Funded
    25.2     Private Insurance
    25.3     Out-of-Pocket

*Additional insights provided are customisable as per client requirements.

* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.

**The supplier list is not exhaustive. Moreover, we can provide analysis of companies as per custom requests.